MOUNTAIN VIEW, Calif., May 16 CA-MAPP-Citi-Conferen
MOUNTAIN VIEW, Calif., May 16 /PRNewswire-FirstCall/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will
present at the 2008 Citi Investment Research Global Healthcare Conference on
Wednesday, May 21, 2008, at 9:00 am (ET) in New York City.
A live webcast of the presentation will be available on the Investor
Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com.
A replay will also be available within 24 hours for seven days following the
presentation.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals develops and plans to commercialize new therapies for
children and adults who suffer from chronic conditions that it believes are
not adequately treated by currently available medicines. The Company applies
its proprietary inhalation technologies to enhance the therapeutic benefits
and commercial attractiveness of proven drugs while minimizing risk by
capitalizing on their known safety, efficacy and commercialization history.
MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004,
in late stage development for the potential treatment of pediatric asthma and
migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug
candidate in early clinical development for the treatment of asthma and
chronic obstructive pulmonary disease.
Additional information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
SOURCE MAP Pharmaceuticals, Inc.
